Pentoxifylline lowers plasminogen activator inhibitor 1 levels in obese individuals: A pilot study

James A.S. Muldowney*, Qingxia Chen, Dana L. Blakemore, Douglas E. Vaughan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Plasminogen activator inhibitor 1 (PAI-1), the primary inhibitor of fibrinolysis and C-reactive protein (CRP), is a predictor of myocardial infarction. Both are upregulated by tumor necrosis factor-alpha (TNF-α) within the obese population. This pilot study tested the hypothesis that TNF-α blockade with pentoxifylline lowers PAI-1 and high-sensitivity CRP (hsCRP) in obese individuals. Twenty participants were treated with pentoxifylline for 8 weeks. A proportional odds model was used to compare the change in PAI-1 and CRP in the pentoxifylline and placebo groups. Plasminogen activator inhibitor 1, but not hsCRP levels, decreased over the 8-week period of the study (P = .025 and P = NS). There was significant dropout of participants due to drug tolerability. These findings suggest that these markers of cardiovascular risk are differentially regulated in obesity and that PAI-1 levels can be reduced by pentoxifylline in this population.

Original languageEnglish (US)
Pages (from-to)429-434
Number of pages6
Issue number6
StatePublished - Aug 2012


  • C-reactive protein
  • fibrinolysis
  • inflammation
  • pentoxifylline
  • plasminogen activator inhibitor 1

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Pentoxifylline lowers plasminogen activator inhibitor 1 levels in obese individuals: A pilot study'. Together they form a unique fingerprint.

Cite this